Urinary biomarkers for early detection of platinum based drugs induced nephrotoxicity

Abdelsalam, Mostafa; Elmorsy, Ekramy; Abdelwahab, Hassan; Algohary, Osman; Naguib, M.; Wahab, Asrul Abdul; Eldeeb, Ahmed; Eltoraby, Ehab E; Abdel-Salam, A. M.; Sabry, Alaa; Elmetwally, Mohamed; Akl, Mohamed Farouk; Anber, Nahla Hamed; Zaki, Maysaa El Sayed; Almutairi, Fahad M.; Mansour, Tamer

doi:10.1186/s12882-018-1022-2

Cited by 24 publications

(28 citation statements)

References 36 publications

(30 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Its soluble form is a 90 kDa molecule (as compared to the membrane bound 104 kDa form) found in the urine of both animals and humans with renal injury. Its presence was associated with AKI in several experimental studies [34,41,42,43,44,45,46,47,48,49,50] and some authors suggest that it may be predictive of cisplatin nephrotoxicity [119,120,121,122,123,124,125,126,127,128,129,130,131,132,133,134,135]. Anti-KIM-1 antibodies have been developed as a potential therapy in neoplasia characterized by KIM-1 overexpression (renal, ovarian, and lung carcinomas) [167,168].…”

Section: Discussionmentioning

confidence: 99%

“…Importantly, it seems that KIM-1 elevations precede sCr rise [125]. A different study showed that high-mobility group box protein 1 (HMGB1), NGAL, and KIM-1 increased significantly one day after a 10 μM dose of cisplatin [126]. HMGB1 showed a more rapid and significant increase, of nearly seven times higher at six hours, compared to KIM-1, that nearly doubled its levels after 24 h.…”

Section: Assessment Of Kim-1 In Cisplatin-induced Nephrotoxicitymentioning

confidence: 99%

See 1 more Smart Citation

The Predictive Role of the Biomarker Kidney Molecule-1 (KIM-1) in Acute Kidney Injury (AKI) Cisplatin-Induced Nephrotoxicity

Tănase

Gosav

Radu

et al. 2019

IJMS

102

View full text Add to dashboard Cite

Acute kidney injury (AKI) following platinum-based chemotherapeutics is a frequently reported serious side-effect. However, there are no approved biomarkers that can properly identify proximal tubular injury while routine assessments such as serum creatinine lack sensitivity. Kidney-injury-molecule 1 (KIM-1) is showing promise in identifying cisplatin-induced renal injury both in vitro and in vivo studies. In this review, we focus on describing the mechanisms of renal tubular cells cisplatin-induced apoptosis, the associated inflammatory response and oxidative stress and the role of KIM-1 as a possible biomarker used to predict cisplatin associated AKI.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Assessment Of Kim-1 In Cisplatin-induced Nephrotoxicitymentioning

confidence: 99%

The Predictive Role of the Biomarker Kidney Molecule-1 (KIM-1) in Acute Kidney Injury (AKI) Cisplatin-Induced Nephrotoxicity

Tănase

Gosav

Radu

et al. 2019

IJMS

102

View full text Add to dashboard Cite

show abstract

“…13 The sample size was calculated by MedCalc software version 19.1.3. According to results of relevant studies 1,14 by considering a error of 5%, study power of 80% (b ¼ 0.20), and assuming area under curve (AUC) 0.8, null hypothesis value 0.5, the ratio of negative/ positive group 3, the total sample size of 36 patients was calculated.…”

Section: Methodsmentioning

confidence: 99%

Evaluation of urinary neutrophil gelatinase-associated lipocalin and urinary kidney injury molecule-1 as biomarkers of renal function in cancer patients treated with cisplatin

Ghadrdan

Ebrahimpour²,

Sadighi

et al. 2020

J Oncol Pharm Pract

View full text Add to dashboard Cite

Introduction Cisplatin-associated acute kidney injury (AKI) is the major limitation to the use of cisplatin-based chemotherapy regimens. Serum creatinine as a traditional marker did not increase in a timely enough fashion in AKI patients. Therefore, recently, the novel markers such as neutrophil gelatinase-associated lipocalin (NGAL) and kidney injury molecule-1 (KIM-1) were considered for early detection of AKI. The aim of this study was to compare the sensitivity and specificity of urinary NGAL and KIM-1 with serum creatinine in cisplatin related AKI. Methods Patients ≥18 years with solid tumors who received cisplatin-based chemotherapy were included. Urine samples were collected 0, 6 and 24 h after cisplatin infusion and the urinary NGAL, KIM-1, and creatinine concentrations were evaluated. NGAL and KIM-1 concentrations were adjusted based on urine creatinine to eliminate hydration effects. Serum creatinine levels were assessed at the base and 72 h after cisplatin administration. Results Seven out of the 35 recruited patients (20%) suffered from AKI defined by Acute Kidney Injury Network criteria. In AKI patients, the ratio of urinary KIM-1–creatinine at 24 h compared to baseline (24 h/baseline) and NGAL–creatinine 24 h/baseline were significantly higher than those of non-AKI group ( p = 0.037 and 0.047 respectively). The area under the receiver-operating characteristic curve for KIM-1–creatinine 24 h/baseline and NGAL–creatinine 24 h/baseline were 0.78 (0.59–0.96, p = 0.032) and 0.77 (0.57–0.97, p = 0.036) respectively. Conclusions Our findings showed that the changes in urinary NGAL–creatinine and KIM-1–creatinine ratios, 24 h after cisplatin administration can be utilized to predict AKI in cisplatin recipients.

show abstract

“…Другие авторы показали, что площадь под ROC-кривой uKIM-1 в диагностике ОПН, вызванной цисплатином у больных раком легкого, значимо выше, чем аналогичный показатель у NGAL, NAG и β2-микроглобулина [75]. Терапия препаратами платины у 26,5 % больных с различными злокачественными опухолями осложнилась повреждением почек, сопровождаясь ростом уровня сывороточного креатинина на 3-й день после введения препарата [76]. Уровень uKIM-1 у них значительно повысился (на 44,23 % от исходного) раньше -за 2 дня до подъема креатинина.…”

unclassified

“…Уровень uKIM-1 у них значительно повысился (на 44,23 % от исходного) раньше -за 2 дня до подъема креатинина. Уровень uKIM-1 оказался самым чувствительным маркером для раннего выявления ОПН, индуцированной платиной, по сравнению с NGAL и цистатином C [76]. Другие авторы на основании полученных данных заключают, что уровень uKIM-1, измеренный через 1 сут после начала инфузии, может быть использован для ранней диагностики ОПН, индуцированной метотрексатом [77].…”

unclassified

KIM-1 as a potential serological/urinological tumor-associated marker of renal cell carcinoma and chemotherapy nephrotoxicity

et al. 2019

View full text Add to dashboard Cite

Контакты: Мариям Павловна Солохина solomar59@mail.ruПоследние десятилетия активно ведутся поиски высокочувствительных и специфичных уринологических и серологических опухолеассоциированных маркеров почечно-клеточного рака. В данном обзоре проведен анализ результатов исследования традиционных серологических опухолеассоциированных маркеров и нового потенциального опухолеассоциированного маркера почечно-клеточного рака -молекулы повреждения почек 1 (kidney injury molecule-1, KIM-1). Описаны структура, источники и функции KIM-1 в норме и при повреждении почечных канальцев, ее возможная роль в канцерогенезе. Проанализирован опыт использования KIM-1 в уточняющей диагностике наиболее распространенных гистологических типов почечно-клеточного рака. Представлены данные, касающиеся экспрессии KIM-1 при злокачественных новообразованиях других локализаций и при заболеваниях почек неонкологического генеза. Показана роль KIM-1 в ранней диагностике нефротоксичного действия противоопухолевых препаратов. Накопленные данные открывают перспективы использования KIM-1 в клинической онкологии как уринологического и серологического маркера почечно-клеточного рака и нефротоксичности химиотерапии. Ключевые слова: почечно-клеточный рак, опухолеассоциированный маркер, KIM-1, заболевание почек, нефротоксичность химиотерапии Для цитирования: Солохина М.П., Сергеева Н.С., Маршутина Н.В. и др. KIM-1 как потенциальный серологический/уринологический опухолеассоциированный маркер почечно-клеточного рака и нефротоксичности химиопрепаратов. Онкоурология 2019;15(3):132-42.The last decades are characterized by an active search for highly sensitive and specific urinological and serological tumor-associated markers of renal cell carcinoma. This review analyses the results of studies of traditional serological tumor-associated markers and a potential new tumor-associated marker of renal cell carcinoma: kidney injury molecule-1, or KIM-1. The structure, sources and functions of KIM-1 in normal conditions and in damaged renal tubules, its potential role in carcinogenesis are described. The experience of using KIM-1 for specifying diagnosis of the most common histological types of renal cell carcinoma is analyzed. Data on KIM-1 expression in malignant tumors in other locations and non-oncological kidney disorders are presented. The role of KIM-1 in early diagnosis of nephrotoxic effect of antitumor drugs is described. The accumulated data is promising in regards to using KIM-1 in clinical oncology as a urinological and serological marker of renal cell carcinoma and chemotherapy nephrotoxicity. For citation: Solokhina M.P., Sergeeva N.S., Marshutina N.V. et al. KIM-1 as a potential serological/urinological tumor-associated marker of renal cell carcinoma and chemotherapy nephrotoxicity. Onkourologiya = Cancer Urology 2019;15(3):132-42.

show abstract

Urinary biomarkers for early detection of platinum based drugs induced nephrotoxicity

Cited by 24 publications

References 36 publications

The Predictive Role of the Biomarker Kidney Molecule-1 (KIM-1) in Acute Kidney Injury (AKI) Cisplatin-Induced Nephrotoxicity

The Predictive Role of the Biomarker Kidney Molecule-1 (KIM-1) in Acute Kidney Injury (AKI) Cisplatin-Induced Nephrotoxicity

Evaluation of urinary neutrophil gelatinase-associated lipocalin and urinary kidney injury molecule-1 as biomarkers of renal function in cancer patients treated with cisplatin

KIM-1 as a potential serological/urinological tumor-associated marker of renal cell carcinoma and chemotherapy nephrotoxicity

Contact Info

Product

Resources

About